Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from JW (Cayman) Therapeutics Co. Ltd. ( (HK:2126) ).
JW Therapeutics presented promising data from its JWCAR201 study at the American Society of Hematology Annual Meeting. The study, which involved patients with relapsed/refractory diffuse large B-cell lymphoma, showed a 100% overall response rate and an 85.7% complete response rate, with manageable safety profiles. These results highlight the potential for JWCAR201 to advance to the Investigational New Drug stage, offering hope for patients with limited treatment options.
The most recent analyst rating on (HK:2126) stock is a Hold with a HK$3.00 price target. To see the full list of analyst forecasts on JW (Cayman) Therapeutics Co. Ltd. stock, see the HK:2126 Stock Forecast page.
More about JW (Cayman) Therapeutics Co. Ltd.
JW (Cayman) Therapeutics Co. Ltd is an independent biotechnology company focused on developing, manufacturing, and commercializing cell immunotherapy products.
Average Trading Volume: 2,153,979
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.28B
See more data about 2126 stock on TipRanks’ Stock Analysis page.